Polar Capital’s Summit Therapeutics SMMT Stock Holding History

Polar Capital’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$17.2M	Buy	5,000,000 +500,000	+11%	+$1.73M	0.13%	144
2020 Q2	$13.4M	Buy	4,500,000 +1,000,000	+29%	+$3.45M	0.12%	154
2020 Q1	$8.29M	Buy	3,500,000 +3,200,000	+1,067%	+$5.5M	0.09%	178
2019 Q4	$480K	Hold	300,000	–	–	﹤0.01%	274
2019 Q3	$537K	Sell	300,000 -44,681	-13%	-$60.4K	﹤0.01%	267
2019 Q2	$436K	Sell	344,681 -5,319	-2%	-$8.9K	﹤0.01%	272
2019 Q1	$641K	Hold	350,000	–	–	0.01%	254
2018 Q4	$403K	Hold	350,000	–	–	﹤0.01%	250
2018 Q3	$777K	Hold	350,000	–	–	0.01%	259
2018 Q2	$858	Hold	350,000	–	–	0.01%	250
2018 Q1	$4.51M	Buy	350,000 +250,000	+250%	+$3.12M	0.05%	221
2017 Q4	$1.11M	Hold	100,000	–	–	0.01%	243
2017 Q3	$1.25M	Buy	+100,000	New	+$1.3M	0.01%	233

Other funds holding SMMT

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BBR Partners New York $1.79B AUM 16.83% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Polar Capital's SMMT Position: Q3 2020 in Review

Polar Capital increased its Summit Therapeutics (SMMT) stake by 11% in Q3 2020, buying an estimated $1.73M and bringing the position to 5,000,000 shares worth $17.2M. The position accounts for 0.13% of the portfolio, ranked #144.

Polar Capital first reported a position in SMMT in Q3 2017 and has held it in 13 quarters since. 19 funds tracked by Wall St. Rank hold SMMT as of Q3 2020.

Polar Capital held 5,000,000 shares of Summit Therapeutics worth $17.2M as of Q3 2020.
Polar Capital bought 500,000 Summit Therapeutics shares in Q3 2020, an estimated $1.73M.
Summit Therapeutics made up 0.13% of Polar Capital's portfolio in Q3 2020, its #144 holding.
Polar Capital first reported a position in Summit Therapeutics in Q3 2017 and has held it in 13 quarters since.
19 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.